Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024)
Zoetis (ZTS) posted quarterly Income from Non-Controlling Interests of $10.0 million for Q3 2024, up 600.0% quarter-over-quarter from -$2.0 million in Q4 2023.
Zoetis (ZTS) Income from Non-Controlling Interests (2012 - 2024) Analysis & Trends
Zoetis (ZTS) has reported Income from Non-Controlling Interests for 12 consecutive years, with $10.0 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Income from Non-Controlling Interests changed N/A year-over-year to $10.0 million; the TTM figure through Jun 2025 stood at $10.0 million (up 600.0% YoY), while the FY2024 annual figure was $10.0 million, up 350.0% from the prior year.
- Income from Non-Controlling Interests advanced to $10.0 million in Q3 2024 per ZTS's latest filing, from -$2.0 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $10.0 million in Q3 2024 and bottomed at -$2.0 million in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged -$166666.7 across 5 years, with a median of -$1.0 million in 2020.
- Annual changes were most pronounced in 2021 — Income from Non-Controlling Interests changed 0.0% — and 2023, when it tumbled 100.0%.
- Zoetis' Income from Non-Controlling Interests stood at -$1.0 million in 2020, then changed by 0.0% to -$1.0 million in 2021, then changed by 0.0% to -$1.0 million in 2022, then sank by 100.0% to -$2.0 million in 2023, then surged by 600.0% to $10.0 million in 2024.
- Business Quant data shows ZTS's Income from Non-Controlling Interests at $10.0 million in Q3 2024, -$2.0 million in Q4 2023, and -$1.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 10.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | -1.00 Mn |
| Dec 31, 2022 | -1.00 Mn |
| Sep 30, 2022 | -1.00 Mn |
| Mar 31, 2022 | -1.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Jun 30, 2021 | -1.00 Mn |
| Mar 31, 2021 | -1.00 Mn |
| Dec 31, 2020 | -1.00 Mn |
| Jun 30, 2020 | -1.00 Mn |
| Jun 30, 2018 | -2.00 Mn |
| Mar 31, 2018 | -2.00 Mn |
| Dec 31, 2017 | -1.00 Mn |
| Oct 1, 2017 | -2.00 Mn |
| Apr 2, 2017 | 1.00 Mn |
| Oct 2, 2016 | -2.00 Mn |
| Dec 31, 2015 | -2.00 Mn |
| Sep 27, 2015 | 1.00 Mn |